Hansoh Pharmaceutical Expands RSU Share Pool With Market Purchases

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has issued an announcement.

Hansoh Pharmaceutical has disclosed that the trustee of its post-IPO restricted share unit scheme purchased 370,000 shares on the open market between April 14 and April 22, 2026, at an average price of about HK$39.11 per share, for a total consideration of roughly HK$14.47 million. Together with a recent issuance of 9 million shares to the scheme trustee, this transaction increases the pool of shares available for future RSU awards, signaling the company’s continued use of equity incentives to retain and motivate selected personnel while only minimally diluting existing shareholders.

The RSU trustee’s holdings rose from 1,194,647 shares before the purchases to 10,564,647 shares afterward, representing a small fraction of Hansoh’s total issued share capital. The board stated it will continue to determine future RSU grants and any further market purchases at its discretion, underscoring an ongoing commitment to share-based compensation as part of the company’s broader talent and governance strategy.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$47.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a China-based biopharmaceutical company listed in Hong Kong, focusing on the research, development, manufacturing and commercialization of innovative and generic medicines. Its portfolio targets key therapeutic areas such as oncology, central nervous system diseases, anti-infectives and other chronic conditions, serving both domestic and international markets.

Average Trading Volume: 9,574,050

Technical Sentiment Signal: Buy

Current Market Cap: HK$223.5B

See more data about 3692 stock on TipRanks’ Stock Analysis page.